EZH2 and cancer: Several synthetic lethal strategies are being developed for ARID1A deficient cancers, including PAPR inhibitors [24], EZH2 inhibitors [127], BET inhibitors [128], ATR inhibitors [37], and inhibitors of HDAC2 [129] and 6 [130].